US 12,329,751 B2
Topical roflumilast formulation having antifungal properties
David Reuben Berk, Westlake Village, CA (US); Patrick Eugene Burnett, Westlake Village, CA (US); Saori Kato, Westlake Village, CA (US); and David W. Osborne, Fort Collins, CO (US)
Assigned to ARCUTIS BIOTHERAPEUTICS, INC., Westlake Village, CA (US)
Filed by ARCUTIS BIOTHERAPEUTICS, INC., Westlake Village, CA (US)
Filed on Jun. 15, 2023, as Appl. No. 18/335,315.
Application 18/335,315 is a continuation of application No. 17/542,072, filed on Dec. 3, 2021, granted, now 11,707,454.
Claims priority of provisional application 63/121,299, filed on Dec. 4, 2020.
Prior Publication US 2023/0321057 A1, Oct. 12, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/44 (2006.01); A61K 9/00 (2006.01); A61K 31/137 (2006.01); A61K 31/27 (2006.01); A61K 31/343 (2006.01); A61K 31/4174 (2006.01); A61K 31/4418 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/60 (2006.01); A61K 33/04 (2006.01); A61K 45/06 (2006.01); A61K 47/06 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/24 (2006.01)
CPC A61K 31/44 (2013.01) [A61K 9/0014 (2013.01); A61K 31/137 (2013.01); A61K 31/27 (2013.01); A61K 31/343 (2013.01); A61K 31/4174 (2013.01); A61K 31/4418 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/60 (2013.01); A61K 33/04 (2013.01); A61K 45/06 (2013.01); A61K 47/06 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/24 (2013.01)] 40 Claims
 
1. A method of treating a fungal infection or overgrowth in a subject in need thereof, comprising topically administering to the subject, a composition comprising an antifungal effective amount of roflumilast or a pharmaceutically acceptable salt thereof, wherein the subject is suffering from seborrheic dermatitis, and wherein the fungal infection or overgrowth is caused by Malassezia species.